Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005;10:40.
Hashimoto K et al: Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013;263:367.
Herman EJ et al: Metabotropic glutamate receptors for new treatments in schizophrenia. Handb Exp Pharmacol 2012;213:297.
Hermanowicz S, Hermanowicz N: The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease. Expert Rev Neurother 2016;16:625.
Hovelsø N et al: Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol 2012;10:12.
Javitt DC: Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol 2012;213:367.
Kane JM et al: Overview of shortand long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res 2016;174:93.
Karam CS et al: Signaling pathways in schizophrenia: Emerging targets and therapeutic strategies. Trend Pharmacol Sci 2010;31:381.
Lao KS et al: Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. CNS Drugs 2016;30:1043.
Lieberman JA et al: Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008;60:358.
Lieberman JA et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209.
McKeage K, Plosker GL: Amisulpride: A review of its use in the management of schizophrenia. CNS Drugs 2004;18:933.
Meltzer HY: Treatment of schizophrenia and spectrum disorders: Pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry 1999;46:1321.
Meltzer HY, Massey BW: The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011;11:59.
Meltzer HY et al: A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274.
Newcomer JW, Haupt DW: The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480.
Pimavanserin (Nuplazid) for Parkinson’s disease psychosis. Med Lett Drugs Ther 2016;58:74.
Schwarz C et al: Valproate for schizophrenia. Cochrane Database Syst Rev 2008;3:CD004028.
Urichuk L et al: Metabolism of atypical antipsychotics: Involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9:410.